Full Press Release Details
Immatics Reports Clinical Responses across Multiple Solid Tumor Types in Ongoing ACTengine IMA203 Phase 1a Trial Targeting PRAME.
IMTX
Immatics Reports Clinical Responses across Multiple Solid Tumor Types in Ongoing ACTengine IMA203 Phase 1a Trial Targeting PRAME
Key Takeaway: Immatics Reports Clinical Responses across Multiple Solid Tumor Types in Ongoing ACTengine IMA203 Phase 1a Trial Targeting PRAME
Price reaction · baseline $12.57 (2021-11-08 close) · hit after-hours · clean, no other IMTX news in the window
day 0 close · peak
-13.9%
day 1
-12.1%
day 3
-7.1%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+20%
120-day peak, hindsight
Typical move
3.9%
average across 7 past catalysts
Lead asset
IMA401
Phase 1 · Refractory Cancer